Lessons learned from the development of imatinib
- 31 May 2004
- journal article
- review article
- Published by Elsevier in Leukemia Research
- Vol. 28, 29-38
- https://doi.org/10.1016/j.leukres.2003.10.002
Abstract
No abstract availableThis publication has 63 references indexed in Scilit:
- Mutational Analysis of the Tyrosine Kinome in Colorectal CancersScience, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- The Hallmarks of CancerCell, 2000
- Stereoselective Synthesis of over Two Million Compounds Having Structural Features Both Reminiscent of Natural Products and Compatible with Miniaturized Cell-Based AssaysJournal of the American Chemical Society, 1998
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998
- Phenylamino‐Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC)Archiv der Pharmazie, 1996